HEALTHMay 26 · 08:30 UTCSTAT NEWSBrittany Trang

STAT+: An AI biotech CEO sets the record straight on AI drug development hype

Peyton Greenside, CEO of BigHat Biosciences, critiques the hype around AI-driven drug development, emphasizing that while AI can rapidly design proteins, the actual drug-making process remains time-consuming and costly. The company, founded in 2019, partners with major pharmaceutical firms like Johnson & Johnson, Merck, and Amgen.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Peyton GreensidepersonBigHat BiosciencesorganizationJohnson & JohnsonorganizationMerckorganizationAmgenorganizationAbbvieorganizationLillyorganizationAI drug developmenttopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSMay 18 · 13:11 UTC
STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
HEALTHMay 14 · 11:00 UTC
STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
BUSINESSMay 12 · 08:30 UTC
Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
HEALTHMay 21 · 18:53 UTC
Guarding biotech from China and big bets in longevity
BUSINESSApr 27 · 11:25 UTC
Novo-Backed Biotech Hemab Seeks to Raise $212 Million in US IPO
BUSINESSMay 18 · 08:30 UTC
STAT+: The China question is tearing biotech apart